Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketinsiderspress.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketInsidersPress.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX and more..
Recent VTYX Stock Price: $36.85
Summary: Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company's clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc. is headquartered in Encinitas, California.
Alex Thompson analyst at Stifel Nicolaus reiterates coverage on Ventyx Biosciences (VTYX) stock in the energy sector with a Buy rating and has set VTYX's stock price target at $ 53.
TipRanks.com reports that Ventyx Biosciences currently has 7 analysts offering 12-month price targets on VTYX and the consensus is a Strong Buy rating with an average stock price target of $53.71. The most recent VTYX stock price we have is $36.85 and we are not making any VTYX forecasts at this time.
In addition, TradingView issued a n/a rating for VTYX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VTYX. marketinsiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on VTYX, please click here >>
Altimmune, ALT
Recent ALT Stock Price: $13.67
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
Patrick Trucchio analyst at H.C. Wainwright reiterates coverage on Altimmune (ALT) stock in the energy sector with a Buy rating and has set ALT's stock price target at $ 50.
TipRanks.com reports that Altimmune currently has 6 analysts offering 12-month price targets on ALT and the consensus is a Strong Buy rating with an average stock price target of $31.67. The most recent ALT stock price we have is $13.67 and we are not making any ALT forecasts at this time.
In addition, TradingView issued a n/a rating for ALT over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALT. marketinsiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ALT, please click here >>
Regeneron, REGN
Recent REGN Stock Price: $710.3
Summary: Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
John Newman analyst at Canaccord Genuity reiterates coverage on Regeneron (REGN) stock in the energy sector with a Buy rating and has set REGN's stock price target at $ 750.
TipRanks.com reports that Regeneron currently has 19 analysts offering 12-month price targets on REGN and the consensus is a Moderate Buy rating with an average stock price target of $762.76. The most recent REGN stock price we have is $710.3 and we are not making any REGN forecasts at this time.
In addition, TradingView issued a n/a rating for REGN over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on REGN. marketinsiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on REGN, please click here >>
G1 Therapeutics, GTHX
Recent GTHX Stock Price: $15.21
Summary: G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC.
David Nierengarten analyst at Wedbush reiterates coverage on G1 Therapeutics (GTHX) stock in the energy sector with a Buy rating and has set GTHX's stock price target at $ 25.
TipRanks.com reports that G1 Therapeutics currently has 5 analysts offering 12-month price targets on GTHX and the consensus is a Moderate Buy rating with an average stock price target of $34.50. The most recent GTHX stock price we have is $15.21 and we are not making any GTHX forecasts at this time.
In addition, TradingView issued a n/a rating for GTHX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on GTHX. marketinsiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on GTHX, please click here >>
Beauty Health, SKIN
Recent SKIN Stock Price: $11.98
Summary: The Beauty Health Company is a beauty health company. Its flagship brand HydraFacial is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. The Beauty Health Company, formerly known as Vesper Healthcare Acquisition Corp., is based in CHICAGO, Utah.
Linda Bolton analyst at D.A. Davidson reiterates coverage on Beauty Health (SKIN) stock in the energy sector with a Buy rating and has set SKIN's stock price target at $ 30.
TipRanks.com reports that Beauty Health currently has 7 analysts offering 12-month price targets on SKIN and the consensus is a Strong Buy rating with an average stock price target of $23.00. The most recent SKIN stock price we have is $11.98 and we are not making any SKIN forecasts at this time.
In addition, TradingView issued a n/a rating for SKIN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SKIN. marketinsiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SKIN, please click here >>
Inari Medical, NARI
Recent NARI Stock Price: $69.6
Summary: Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. Its initial product offering comprises 2 minimally-invasive, novel catheter-based mechanical thrombectomy devices. It built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism or VTE (deep vein thrombosis and pulmonary embolism/ PE). Its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of PE. Its advanced systems & processes to control the key relationships between its sales representatives and treating physicians like cardiologists, radiologists, helps it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals across the U.S.
William Plovanic analyst at Canaccord Genuity reiterates coverage on Inari Medical (NARI) stock in the energy sector with a Buy rating and has set NARI's stock price target at $ 94.
TipRanks.com reports that Inari Medical currently has 5 analysts offering 12-month price targets on NARI and the consensus is a Strong Buy rating with an average stock price target of $94.80. The most recent NARI stock price we have is $69.6 and we are not making any NARI forecasts at this time.
In addition, TradingView issued a n/a rating for NARI over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NARI. marketinsiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on NARI, please click here >>
The editors at marketinsiderspress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketInsidersPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information including insider trades news on top moving stocks. All information is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to MarketInsidersPress.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================